(ANIX) Anixa Biosciences - Ratings and Ratios

Anixa Biosciences, Inc. (NASDAQ:ANIX) is a biotechnology company specializing in the development of innovative therapies and vaccines targeting critical unmet needs in oncology. Its lead therapeutic program focuses on a chimeric endocrine receptor-T cell (CER-T) therapy, a novel approach within the chimeric antigen receptor-T (CAR-T) technology space, designed to address ovarian cancer. The companys vaccine portfolio includes a breast cancer vaccine initially targeting triple-negative breast cancer (TNBC), the most aggressive and lethal form of breast cancer, as well as a vaccine for ovarian cancer. Anixa is also advancing a broader vaccine discovery program aimed at identifying additional retired proteins associated with other cancers, with a focus on high-incidence malignancies such as lung, colon, and prostate cancers. The company, formerly known as ITUS Corporation, rebranded as Anixa Biosciences, Inc. in October 2018, and has been operational since its incorporation in 1982. Headquartered in San Jose, California, Anixa leverages its proprietary technologies to identify and develop cancer-associated proteins for vaccine and therapeutic applications.

3-Month Forecast: Based on , Anixas stock has shown recent price fluctuations, with the SMA 20 (3.04) slightly above the SMA 50 (2.76), indicating potential short-term upward momentum. However, the SMA 200 (2.95) suggests a longer-term sideways trend. The ATR (0.21) reflects moderate volatility. From a perspective, the companys high P/B ratio (4.91) and P/S ratio (481.54) highlight its speculative nature, while the negative RoE (-62.78) signals ongoing operational challenges. Over the next three months, expect continued volatility, with potential upside driven by clinical trial updates or partnership announcements. However, the lack of forward P/E and high valuation multiples suggest caution, as the stock remains sensitive to broader market conditions and biotechnology sector trends.